EUROPEAN SOCIETY FOR CLINICAL VIROLOGY
Promote public health and advance public medical education by: Improving knowledge of viruses, especially diagnosis and management of viral diseases, pathogenesis, natural history and prevention; Improving diagnostic methods; Promoting high standards in laboratory viral diagnosis through quality assessment activities, education and development of reference standards.
Financial health, per its FY2025 accounts
The accounts state that the charity reported a net loss of £117,868 for the year ended 31 October 2025. Free reserves decreased from £27,466 to £47,296 (converted from EUR 53,759), though the document notes a foreign exchange conversion impact. The filing admits to an audit exemption under the small companies regime.
What the accounts disclose
“The Executive has the policy to maintain sufficient funds to allow the Society to meet its objectives and obligations on a long-term basis, and to provide a measure of investment income.” — page 4
Trustees
- Dr Annelies Riezebos-Brilman
- Dr Catherine Moore
- Dr Heli Harvala
- Dr Mario Hoenemann
- Dr Xavier Lopez Labrador
- Professor George Sourvinos
- Professor Jerome Le Goff
- Professor Pamela Josephine Vallely
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/10/2025 | £62k | £43k |
| 31/10/2024 | £61k | £178k |
| 31/10/2023 | £73k | £199k |
| 31/10/2022 | £106k | £57k |
| 31/10/2021 | £22k | £53k |
Common questions
Is EUROPEAN SOCIETY FOR CLINICAL VIROLOGY financially healthy?
Per its FY2025 accounts: The accounts state that the charity reported a net loss of £117,868 for the year ended 31 October 2025. Free reserves decreased from £27,466 to £47,296 (converted from EUR 53,759), though the document notes a foreign exchange conversion impact. The filing admits to an audit exemption under the small companies regime.